Bladder Stone Removal in India
Get Bladder Stone Removal at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Bladder Stone Removal in UAE
Bladder Stone Removal at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Bladder stone removal encompasses a spectrum of minimally invasive and surgical procedures—including cystolitholapaxy, transurethral lithotripsy, and open cystolithotomy—that achieve stone clearance rates exceeding 95% in experienced hands. International patients choose India and the UAE through GAF Healthcare because both destinations combine JCI-accredited tertiary urology centres, subspecialty-trained endourologists, and state-of-the-art holmium laser and pneumatic lithotripsy platforms with dramatically shorter waiting times than most Western health systems. GAF Healthcare coordinates every clinical and logistical touchpoint—from pre-travel diagnostic review to post-discharge teleconsultation—ensuring a seamless, medically supervised journey for patients arriving from across Europe, Africa, the Middle East, and beyond.
Hospital Stay: 1–3 days (day-case to overnight for endoscopic procedures; 3–5 days for open surgery in complex cases) • Total Stay in Country (Fit-to-Fly): 1–2 weeks for minimally invasive approaches; 3–4 weeks following open cystolithotomy • Success Rate: 95–98% stone-free rate for cystolitholapaxy with holmium laser; >90% for percutaneous approaches in large or complex stones
What Is It?
Bladder calculi are mineralised concretions that form within the urinary bladder, most commonly as a consequence of urinary stasis, bladder outlet obstruction (due to benign prostatic hyperplasia, urethral stricture, or neurogenic bladder dysfunction), recurrent urinary tract infections caused by urease-producing organisms (Proteus mirabilis, Klebsiella spp.), or the presence of a foreign body such as a migrated suture or long-term catheter. The stones are predominantly composed of struvite (magnesium ammonium phosphate), uric acid, calcium oxalate, or mixed matrices, and they range from millimetric particles to multi-centimetre concretions weighing several hundred grams. Physiologically, an obstructing or irritating calculus triggers a cascade of detrusor overactivity, haematuria, dysuria, interrupted urinary stream, suprapubic pain, and—if left untreated—ascending pyelonephritis, hydronephrosis, and progressive renal impairment.
The global standard of care has shifted decisively toward endoscopic stone removal. Rigid or flexible cystoscopy combined with holmium:YAG laser lithotripsy (Ho:YAG, wavelength 2,140 nm) is now the preferred first-line modality for stones up to 3–4 cm, offering precise photothermal fragmentation with negligible thermal spread to surrounding mucosa. Pneumatic (ballistic) lithotripsy using pneumatic probes and ultrasonic lithotripsy are effective adjuncts or alternatives in appropriately selected patients. Percutaneous suprapubic cystolithotomy (PCCL) is reserved for very large stones (>4 cm), paediatric cases, or where the urethra cannot accommodate a working cystoscope. Open cystolithotomy—once the standard—is now infrequently performed and is restricted to stones that are refractory to endoscopic management or that coexist with structural bladder pathology requiring simultaneous open correction.
Critically, stone removal is only one component of comprehensive management. The underlying aetiology—most commonly bladder outlet obstruction from BPH—must be addressed concurrently or sequentially (e.g., transurethral resection of the prostate, TURP, or holmium laser enucleation of the prostate, HoLEP) to prevent recurrence rates that otherwise exceed 50% within five years. Metabolic workup including 24-hour urine stone risk profile (calcium, oxalate, urate, citrate, pH, volume) and serum biochemistry guides pharmacological prophylaxis such as thiazide diuretics for hypercalciuria, allopurinol for hyperuricosuria, or citrate supplementation to raise urinary pH above 6.5.
Candidates
• ELIGIBLE PATIENTS:
• Adults or paediatric patients with cystoscopically or radiologically confirmed bladder calculi (≥5 mm or symptomatic stones <5 mm unresponsive to conservative measures)
• Patients with lower urinary tract symptoms (LUTS) including haematuria, dysuria, urinary retention, or interrupted stream attributable to bladder calculi on imaging
• Patients with recurrent urinary tract infections (≥2 culture-proven episodes per year) in the setting of known bladder stones
• Patients with concurrent bladder outlet obstruction (BPH, urethral stricture, neurogenic bladder) requiring combined stone removal and outlet reconstruction
• Patients who have failed extracorporeal shock wave lithotripsy (ESWL) for lower ureteric or bladder stones
• Paediatric patients with endemic bladder stones (metabolic or nutritional aetiology) in whom dietary modification alone is insufficient
• REQUIRED PRE-OPERATIVE DIAGNOSTICS:
• Urinalysis and urine culture with sensitivity (mandatory to treat active UTI before elective instrumentation)
• Serum creatinine, eGFR, electrolytes, full blood count, coagulation profile (PT/INR/aPTT)
• Serum PSA (in males ≥45 years to exclude concurrent prostate pathology)
• Non-contrast CT of the kidneys, ureters, and bladder (NCCT-KUB): gold standard — identifies stone number, size, density (Hounsfield units), and position; detects concurrent upper tract calculi
• Ultrasound of kidneys, ureters, and bladder (USS-KUB): first-line in paediatric or radiation-sensitive patients
• Plain abdominal X-ray (KUB radiograph): useful for radio-opaque calculi (calcium oxalate, calcium phosphate, struvite) but misses radio-lucent uric acid stones
• Uroflowmetry and post-void residual (PVR) measurement: quantifies degree of bladder outlet obstruction
• Flexible cystoscopy (diagnostic): direct visualisation of stone burden, bladder mucosa, ureteric orifices, and prostate in selected cases
• 24-hour urine metabolic stone risk profile and serum calcium/uric acid/parathyroid hormone (PTH) for recurrent stone formers
• ECG and anaesthetic assessment (cardiological clearance including echocardiography if indicated for patients with known cardiac disease)
• RELATIVE CONTRAINDICATIONS:
• Active, untreated urinary tract infection (surgery must be deferred until culture-directed antibiotic therapy achieves sterile urine)
• Uncorrected coagulopathy or patients on anticoagulation/antiplatelet therapy who cannot undergo a safe bridging protocol
• Urethral stricture disease that prevents safe passage of a cystoscope without prior urethral dilatation or internal urethrotomy
• Severely contracted bladder (capacity <100 mL) limiting endoscopic manoeuvring space
• Uncontrolled systemic illness (decompensated cardiac failure, advanced hepatic failure, uncontrolled diabetes mellitus) — requires medical optimisation prior to surgery
• Known allergy to contrast medium (relevant if intraoperative fluoroscopy is planned; premedication protocol or CO2 cystography is an alternative)
• Pregnancy (relative — radiation and instrumentation risk must be carefully weighed)
Procedure
ENDOSCOPIC TECHNIQUES (FIRST-LINE STANDARD OF CARE):
1. Transurethral Cystolitholapaxy (TUCL) with Holmium:YAG Laser Lithotripsy
The procedure of choice for stones up to 3–4 cm in adults with a normal urethra. A rigid cystoscope (21–26 Fr) or semi-rigid ureteroscope is introduced under direct vision. The holmium:YAG laser (Ho:YAG, 2,140 nm wavelength, pulse energies 0.5–3.0 J, frequencies 5–20 Hz) delivers photothermal energy that vaporises stone matrix through a 'Moses Effect' photoacoustic mechanism, achieving superior fragmentation and dusting compared to older neodymium:YAG lasers. Fragments are evacuated using an Ellik evacuator or a purpose-built stone removal sheath with continuous irrigation. Operating time: 30–90 minutes. Catheterisation: 1–2 days post-operatively. Stone-free rate: 95–98%.
2. Pneumatic (Ballistic) Lithotripsy
A pneumatically driven metallic probe (e.g., Swiss LithoClast, EMS) delivers kinetic energy to fragment calculi mechanically. Highly effective for hard, dense stones (>1,000 HU on CT). Often combined with ultrasonic aspiration for simultaneous fragmentation and evacuation. Stone-free rate: 88–95%. Best suited for stones 1–3 cm.
3. Electrohydraulic Lithotripsy (EHL)
A spark-gap probe generates a hydraulic shock wave within irrigating fluid. Effective but carries a higher risk of bladder mucosal injury than laser or pneumatic approaches and is therefore used less frequently as a primary modality. Reserved for situations where laser equipment is unavailable.
4. Flexible Cystoscopy with Laser Lithotripsy
Utilised when urethral anatomy precludes rigid instrumentation (e.g., urethral stricture, paediatric patients, prior hypospadias repair). Digital flexible cystoscopes with a 3.6 Fr working channel accommodate 200–272 µm laser fibres. Thulium fibre laser (TFL, 1,940 nm) is an emerging alternative to Ho:YAG, offering higher average power, continuous-wave mode for improved dusting, and superior stone vaporisation efficiency.
MINIMALLY INVASIVE PERCUTANEOUS APPROACHES:
5. Percutaneous Cystolithotomy (PCCL)
Indicrated for very large stones (>4 cm), paediatric bladder stones where urethral calibre limits transurethral access, or neurogenic bladder patients with augmentation cystoplasty. A suprapubic Amplatz sheath (24–30 Fr) is introduced into a distended bladder under ultrasound guidance. Fragmentation using holmium laser, pneumatic lithotripter, or ultrasonic device is performed through the percutaneous access. Stone-free rates: >92%. Hospital stay: 2–4 days. Requires bladder drainage for 3–5 days post-operatively.
SURGICAL (OPEN) APPROACH:
6. Open Cystolithotomy
Now rarely performed (<5% of cases in experienced centres). Reserved for: (a) massive stones (>6–8 cm) or multiple large stones unamenable to endoscopic clearance in a single session, (b) concurrent open bladder or prostatic surgery (e.g., open simple prostatectomy, bladder diverticulectomy), (c) centres without advanced endoscopic equipment. A suprapubic extraperitoneal or transperitoneal cystotomy is performed under general or spinal anaesthesia. Hospital stay: 3–5 days. Recovery: 3–4 weeks before fit-to-fly.
CONCOMITANT PROCEDURES ADDRESSING UNDERLYING AETIOLOGY:
7. Transurethral Resection of the Prostate (TURP) — Monopolar or Bipolar
Performed simultaneously or staged with stone removal in males with confirmed BPH-related bladder outlet obstruction. Bipolar TURP in normal saline eliminates the risk of TUR syndrome (dilutional hyponatraemia) associated with monopolar TURP using glycine irrigation.
8. Holmium Laser Enucleation of the Prostate (HoLEP)
Increasingly preferred over TURP for larger prostates (>80 mL). Size-independent efficacy and durable long-term outcomes. Can be combined with simultaneous holmium laser cystolitholapaxy in a single operating session.
9. Direct Vision Internal Urethrotomy (DVIU) / Urethral Dilatation
Addresses urethral stricture disease as a contributory aetiology before or concurrent with bladder stone removal.
ADVANCED TECHNOLOGIES AVAILABLE AT GAF PARTNER CENTRES:
• Moses Technology 2.0 (Lumenis): Enhanced Ho:YAG laser pulse modulation reducing stone retropulsion by 80% and improving ablation efficiency
• Thulium Fibre Laser (IPG Photonics / IPG TFL): Next-generation continuous-wave laser enabling superior stone dusting ('powder' technique) — available at select JCI-accredited centres in India and the UAE
• Digital Single-Use Flexible Cystoscopes (Ambu aScope, Olympus LithoVue): Eliminate cross-infection risk; beneficial for immunocompromised patients
• Robotic-Assisted Cystolithotomy: Emerging application of the Da Vinci Xi system for simultaneous bladder stone removal and reconstruction in complex anatomical scenarios (e.g., bladder diverticulum, vesicovaginal fistula repair)
Cost of Bladder Stone Removal: India vs. UAE
The cost of bladder stone removal varies significantly depending on the surgical approach (endoscopic cystolitholapaxy versus percutaneous versus open), the stone burden (number, size, and hardness), the need for concurrent procedures to address underlying bladder outlet obstruction (TURP, HoLEP, DVIU), anaesthetic requirements, and the tier of hospital selected. Both India and the UAE offer world-class urological care at internationally accredited institutions, but the overall cost differential is substantial: patients choosing NABH- or JCI-accredited hospitals in India typically achieve savings of 50–65% compared to equivalent private hospitals in Dubai or Abu Dhabi, without compromising clinical outcomes or technology access. The figures below represent all-inclusive package estimates — encompassing surgeon fees, anaesthetist fees, operating room charges, hospital consumables (laser fibres, lithotripsy probes, irrigation fluid), standard inpatient medications, nursing care, and routine post-operative diagnostic tests — as coordinated through GAF Healthcare.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $1,200 – $3,500 | ~57% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $3,000 – $8,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PRE-TRAVEL PHASE (2–4 WEEKS BEFORE DEPARTURE):
• Step 1 — GAF Healthcare Remote Case Review: Patient submits existing imaging (CT-KUB, ultrasound reports), urinalysis, blood results, and medication list via the GAF secure patient portal. A GAF-affiliated consultant urologist provides a written opinion within 48 hours, including recommended procedure, estimated duration, and suitability for travel.
• Step 2 — Medical Visa / Entry Visa Facilitation: GAF Healthcare prepares and submits the e-Medical Visa application package for India (valid for up to 1 year, triple entry, processed in 3–5 business days) or advises on UAE visa-on-arrival eligibility / UAE visa application for the patient and one accompanying attendant.
• Step 3 — Pre-operative Optimisation: Any active urinary tract infection is treated with culture-directed antibiotics (minimum 5–7 days) prior to travel. Anticoagulant medications (warfarin, direct oral anticoagulants — DOACs — such as rivaroxaban or apixaban) are bridged or discontinued per a cardiologist-approved protocol. Blood glucose optimisation targets HbA1c ≤8.0% in diabetic patients.
• Step 4 — Arrival & Pre-operative Assessment: GAF arranges airport pickup by a trained medical facilitator. Pre-admission blood work, urinalysis, uroflowmetry, post-void residual measurement, ECG, and anaesthetic assessment are completed within the first 24 hours at the partner hospital. Any outstanding imaging (NCCT-KUB if not recently performed) is obtained.
PROCEDURE DAY:
• Step 5 — Anaesthesia: Cystolitholapaxy and percutaneous approaches are most commonly performed under spinal anaesthesia (subarachnoid block, T10 sensory level target), which avoids the risks of general anaesthesia and allows real-time patient cooperation. General anaesthesia (laryngeal mask or endotracheal tube) is used for paediatric patients, patients with spinal pathology, or patient preference. Local anaesthesia with conscious sedation is an option for brief flexible cystoscopy-based procedures.
• Step 6 — Stone Fragmentation & Extraction: The chosen technique (holmium laser cystolitholapaxy, pneumatic lithotripsy, PCCL) is executed under continuous saline irrigation with direct cystoscopic visualisation. Fragmented stone material is evacuated and sent for crystallographic analysis (stone composition analysis guides future metabolic prophylaxis). A flexible cystoscope is routinely passed at procedure end to confirm complete stone clearance ('stone-free status' defined as residual fragments <3 mm on post-operative imaging).
• Step 7 — Concurrent Outlet Obstruction Management: If BPH or urethral stricture is confirmed, TURP, HoLEP, or DVIU is performed in the same session or as a planned staged procedure, per the pre-operative urological plan.
• Step 8 — Urethral Catheterisation: A 16–18 Fr Foley catheter is inserted at procedure end to allow continuous bladder drainage, clear haematuria monitoring, and bladder decompression. Catheter is typically removed at 24–48 hours post-operatively following endoscopic procedures; 3–5 days following PCCL or open cystolithotomy.
POST-OPERATIVE RECOVERY IN HOSPITAL (Days 1–3):
• Step 9 — Immediate Post-op Monitoring: Vital signs, urine colour (haematuria clearance), catheter output, and pain score (NRS) monitored every 4 hours. IV antibiotics (typically a third-generation cephalosporin or aminoglycoside based on pre-operative urine culture) continued for 24–48 hours then transitioned to oral prophylaxis.
• Step 10 — Catheter Trial of Void: Catheter removed at 24–48 hours. A successful trial of void (voided volume >200 mL, PVR <100 mL on bladder scan) is confirmed before discharge. If the patient fails trial of void (typically due to concurrent BPH not yet addressed), a temporary catheter or clean intermittent catheterisation (CIC) protocol is initiated.
• Step 11 — Imaging Confirmation of Stone Clearance: KUB X-ray or targeted ultrasound performed on Day 1–2 post-operatively to confirm stone-free status. CT-KUB is reserved for cases where complete clearance is uncertain.
• Step 12 — Discharge: Most patients undergoing endoscopic cystolitholapaxy are discharged on Day 1–2. PCCL patients are discharged Day 3–4. Open cystolithotomy patients on Day 4–5.
POST-DISCHARGE RECOVERY IN DESTINATION COUNTRY (Weeks 1–2):
• Step 13 — GAF Recovery Accommodation: Patient and attendant are transferred to a GAF-partner serviced apartment or hotel within proximity to the hospital. Hydration instructions (target urine output >2 L/day), dietary guidance (low oxalate, moderate sodium restriction, adequate calcium intake), and oral analgesic/antibiotic regimen are provided in writing in the patient's language.
• Step 14 — First Follow-up Consultation (Day 5–7): Wound check (for PCCL or open cases), urinalysis repeat, and stone composition result review with the urologist. Metabolic prophylaxis (e.g., potassium citrate for uric acid stones, hydrochlorothiazide for hypercalciuria) is initiated if indicated by stone analysis and metabolic workup.
• Step 15 — Fit-to-Fly Assessment: For endoscopic cystolitholapaxy patients, fitness for long-haul flight is typically confirmed at 7–10 days post-procedure (confirmed haematuria resolution, successful voiding, no fever, no DVT risk factors unmitigated). PCCL patients are cleared at 14 days. Open cystolithotomy patients at 21–28 days. A formal fit-to-fly letter is issued by the treating consultant.
POST-RETURN HOME (Weeks 3–12):
• Step 16 — GAF Teleconsultation: A structured teleconsultation is scheduled at 4 weeks and 12 weeks post-procedure to review voiding diary, urinalysis, and any imaging performed at the patient's home country. Results of 24-hour urine metabolic stone risk profile (drawn at home at 6–8 weeks) are reviewed and prophylactic medication adjusted accordingly.
• Step 17 — Annual Surveillance: Patients are advised annual renal and bladder ultrasound and plain KUB X-ray (or low-dose CT-KUB every 2–3 years for recurrent stone formers) to detect recurrence early. Compliance with increased fluid intake (≥2.5 L/day) and dietary modification is reinforced at each contact.
Risks & Considerations
Bladder stone removal is a well-established, low-mortality procedure; however, patients must be counselled on a defined set of procedural and anaesthetic risks to provide valid informed consent. Intraoperative risks include bladder perforation (incidence <1% for rigid cystolitholapaxy; higher for percutaneous approaches), which — when recognised promptly — is managed by prolonged catheter drainage and rarely requires open surgical repair. Haemorrhage significant enough to require transfusion occurs in <0.5% of endoscopic cases but rises to 2–5% for open cystolithotomy in patients on antiplatelet or anticoagulant therapy. Transurethral resection syndrome (TUR syndrome), characterised by dilutional hyponatraemia, altered consciousness, and cardiovascular compromise, is a risk specific to monopolar TURP using hypotonic glycine irrigation; this is largely eliminated by the use of bipolar TURP in isotonic saline or by HoLEP.
Post-operative risks include urinary tract infection (5–15%); risk is mitigated by pre-operative sterile urine confirmation and peri-operative antibiotic prophylaxis (single-dose IV cefazolin or gentamicin at induction per EAU guidelines). Urethral stricture may develop as a delayed complication of urethral instrumentation, particularly in males with pre-existing stricture disease or following multiple endoscopic procedures; the incidence is reduced by the use of adequate lubrication, appropriate instrument calibre, and atraumatic technique. Temporary or prolonged urinary retention following catheter removal, especially if concurrent BPH was not addressed, may require a further trial or clean intermittent catheterisation.
Top Hospitals for Bladder Stone Removal
Top Doctors for Bladder Stone Removal
Internationally trained specialists in Urology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Gaurav Kataria
MCh, MS, MBBS
Urologist
Paras Hospitals, Gurgaon, India
23+ Yearsof experience
Dr. Gaurav Kataria is a Senior Consultant Urologist at Paras Hospitals in Gurgaon with more than 23 years of clinical experience in urological care and genito-urinary surgery. He completed his MCh in Urology from the prestigious Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER) in 2017, building on a strong foundation of MS in General Surgery (2011) and MBBS (2005). His credentials reflect a commitment to advanced surgical… Read more
Dr. Gutta Srinivas
MBBS, MS, DNB
Urologist & Transplant Surgeon
Yashoda Hospitals, Hi-Tech City, Hyderabad, India
25+ Yearsof experience
Dr. Gutta Srinivas is a Senior Consultant Urologist and Transplant Surgeon serving as Clinical Director of the Department of Urology at Yashoda Hospitals, Hi-Tech City, Hyderabad. With over 25 years of clinical experience, he has established himself as a leading figure in urological surgery and renal transplantation across India. His pioneering work includes performing India's first ABO-incompatible kidney transplant using the Adsorbent Technique—a… Read more
Dr. Jangvir Singh Grewal
MBBS, MS in General Surgery, MCh in Urology and Renal Transplant Program, DrNB in Genitourinary Surgery
Urologist
Medanta - The Medicity, Gurugram, India
3+ Yearsof experience
Dr. Jangvir Singh Grewal is an Associate Consultant in Urology at Medanta - The Medicity, Gurugram, where he brings over three years of clinical experience in managing complex urological and renal conditions. He holds an MCh in Urology and Renal Transplant Program from Madurai Medical College (completed 2023), a DrNB in Genitourinary Surgery, and an MS in General Surgery from Pt. B.D. Sharma PGIMS, UHS Rohtak, providing him with a strong surgical… Read more
Dr. Lokesh Sinha
MBBS, MS, DNB
Urologist
Gleneagles Hospital, Mumbai, India
16+ Yearsof experience
Dr. Lokesh Sinha is a Senior Consultant Urologist at Gleneagles Hospital in Mumbai with over 16 years of clinical excellence in urological surgery. He holds a prestigious academic background with MBBS, MS, and DNB qualifications, and was awarded a Gold Medal in MS for General Surgery, reflecting his exceptional surgical skill and commitment to patient care. His surgical practice spans the full spectrum of modern urology, with particular expertise in… Read more
Dr. M. Gopichand
MBBS, MCh (Urology & Andrology), DNB (Urology)
Urologist
Yashoda Hospitals, Hyderabad, India
26+ Yearsof experience
Dr. M. Gopichand is a Senior Consultant Urologist at Yashoda Hospitals in Hyderabad with over 26 years of distinguished clinical practice in urology. He holds an MCh in Urology & Andrology from Bombay Hospital Institute of Medical Sciences and a DNB in Urology from New Delhi, credentials that underpin his comprehensive expertise across the full spectrum of urological diseases. He is recognized as one of South India's most accomplished urologists,… Read more
Frequently Asked Questions — Bladder Stone Removal
The cost of bladder stone removal varies by procedure type, stone complexity, and any concurrent surgery required to address an underlying cause such as benign prostatic hyperplasia. In India, at JCI- or NABH-accredited tertiary hospitals (Apollo, Fortis, Medanta, Manipal), an all-inclusive package for transurethral cystolitholapaxy using holmium:YAG laser typically ranges from USD 1,200 to USD 2,200. If a concurrent procedure such as bipolar TURP or HoLEP is required simultaneously to address bladder outlet obstruction, the combined package ranges from USD 2,000 to USD 3,500. Percutaneous cystolithotomy (PCCL) or open cystolithotomy for very large or complex stones falls between USD 2,500 and USD 3,500. These figures include surgeon fees, anaesthetist, operating room, inpatient stay (1–3 nights), standard medications, and routine post-operative imaging. In the UAE, at JCI-accredited and DHA/DOH-licensed hospitals in Dubai and Abu Dhabi (Cleveland Clinic Abu Dhabi, American Hospital Dubai, Mediclinic City Hospital), the equivalent packages range from USD 3,000 to USD 5,000 for endoscopic cystolitholapaxy, USD 4,500 to USD 7,000 for combined stone removal with TURP or HoLEP, and USD 5,000 to USD 8,000 for percutaneous or open approaches. The UAE commands a premium reflecting the cost of luxury facilities, imported consumables, and higher operational costs, but offers the advantage of geographic proximity for patients from the GCC, Africa, and Eastern Europe. India is typically 50–65% less expensive than the UAE for equivalent procedures and technology. GAF Healthcare provides a personalised cost estimate based on uploaded CT-KUB and diagnostic reports within 48 hours of case submission — with no commitment required.
The minimum safe stay before an international flight (fit-to-fly clearance) depends directly on the surgical approach used and your individual recovery trajectory. For transurethral cystolitholapaxy with holmium:YAG laser — the most commonly performed procedure — most patients are hospitalised for 1–2 nights and are fit for long-haul international flight at 7–10 days post-procedure, provided the following criteria are met: gross haematuria has resolved (urine is clear to faint pink), the urethral catheter has been successfully removed and the patient is voiding normally (post-void residual <100 mL), there is no fever or clinical signs of urinary tract infection, and no unmitigated risk factors for deep vein thrombosis (DVT) or pulmonary embolism are present. A formal fit-to-fly letter is issued by the treating urologist at the Day 7 follow-up consultation. For percutaneous cystolithotomy (PCCL) — used for larger stones — the recommended minimum in-country stay is 14 days, allowing adequate time for the suprapubic track to seal, any haematuria from percutaneous access to resolve, and the cystogram (bladder X-ray with contrast) to confirm watertight bladder closure before catheter removal. For open cystolithotomy — now rarely performed — a 21–28 day post-operative stay in-country is recommended before intercontinental flight. Wound healing, bowel recovery, and DVT prophylaxis (low-molecular-weight heparin such as enoxaparin, continued for 14 days post-discharge) must be completed and confirmed before clearance. For all patients, on the day of long-haul travel GAF Healthcare recommends: adequate oral hydration (500 mL water before boarding), compression stockings (18–23 mmHg graduated compression), and aisle seating to permit hourly ambulation during flights exceeding 4 hours. The treating urologist will issue a medical summary letter (in English and the destination country's language where applicable) to carry in hand luggage throughout travel.
Bladder stone removal — when performed by subspecialty-trained endourologists at accredited centres using modern laser lithotripsy technology — achieves stone-free rates of 95–98% for transurethral cystolitholapaxy with holmium:YAG laser, as reported in contemporary peer-reviewed urological literature and corroborated by outcomes data from JCI-accredited Indian and UAE partner hospitals in the GAF Healthcare network. The internationally accepted definition of 'success' or 'stone-free status' in bladder stone removal is the absence of residual fragments ≥3 mm on post-operative imaging (KUB X-ray or ultrasound performed 24–48 hours after surgery). Fragments smaller than 3 mm are considered clinically insignificant and are expected to pass spontaneously in urine. A stone-free rate of 95–98% for holmium laser cystolitholapaxy means that fewer than 1 in 20–25 patients will require a planned second-look cystoscopy to achieve complete clearance, typically necessitated by a very high stone burden (multiple large fragments) or an exceptionally hard stone matrix (brushite or calcium oxalate monohydrate >1,200 HU on CT). For percutaneous cystolithotomy (PCCL), the stone-free rate in published series ranges from 90–96%, with the slightly lower ceiling reflecting the anatomical complexity of cases selected for percutaneous access. Open cystolithotomy in experienced hands achieves a stone-free rate of >97% for a single procedure but carries higher morbidity than endoscopic approaches. Critically, the procedure's stone-free rate must be distinguished from the long-term recurrence-free rate. Without treatment of the underlying aetiology — most commonly bladder outlet obstruction from BPH — the 5-year stone recurrence rate exceeds 50%. GAF Healthcare's treatment planning therefore mandates that every patient's outlet obstruction and metabolic risk factors are assessed and addressed. When outlet obstruction is definitively treated (via TURP, HoLEP, or DVIU) at the time of or shortly after stone removal, and when pharmacological metabolic prophylaxis is initiated based on 24-hour urine and stone crystallography results, long-term recurrence rates fall to below 15% at five years.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides an integrated, end-to-end medical tourism coordination service that begins well before the patient's flight and continues through post-discharge surveillance at home.
VISA ASSISTANCE: For India, GAF Healthcare's dedicated medical visa team prepares a complete e-Medical Visa application package on behalf of the patient and up to two attendants (family members). The Indian e-Medical Visa (e-MV) is a triple-entry visa valid for 1 year, processed through the Indian government's online portal with approval typically granted in 3–5 business days upon submission of the hospital's invitation letter (which GAF procures directly from the partner hospital's international patient services office), passport copies, passport-size photographs, and proof of funds. For the UAE (Dubai and Abu Dhabi), nationals of over 50 countries — including EU member states, the United Kingdom, United States, Canada, and Australia — receive visa-on-arrival or visa-free entry for 30–90 days. Citizens of other nationalities are supported by GAF's UAE visa application service, which facilitates a medical treatment visa through the Federal Authority for Identity and Citizenship (ICA). GAF provides all required documentation templates, including the official UAE hospital sponsor letter.
AIRPORT TRANSFERS & IN-COUNTRY TRANSPORT: A GAF-assigned medical facilitator meets the patient and attendants at the arrivals hall (Mumbai CSIA, Delhi IGI, Chennai MAA, Bangalore BLR, Dubai DXB, Abu Dhabi AUH — as applicable) holding a personalised GAF Healthcare placard. All ground transfers — airport to hotel, hotel to hospital, inter-facility transfers, and return airport drop — are provided in air-conditioned, GPS-tracked vehicles with wheelchair access available on request at no additional charge.
DEDICATED MEDICAL INTERPRETERS: GAF Healthcare maintains a network of certified medical interpreters covering Arabic, Russian, French, Swahili, Amharic, Bangla, and over 20 additional languages. For rare languages, a trained telephone or video interpretation service is connected in real time during consultations, surgical consent discussions, discharge briefings, and pharmacy interactions. All written materials — discharge summaries, medication instructions, dietary guidelines, follow-up schedules — are translated into the patient's preferred language before departure.
ACCOMMODATION FOR PATIENT AND ATTENDANT: GAF Healthcare has pre-negotiated preferred rates at serviced apartments and partner hotels within 5–15 minutes of each partner hospital in India (Apollo Hospitals campuses in Delhi, Chennai, Hyderabad; Fortis, Medanta, Manipal networks) and in the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai, American Hospital Dubai). Accommodation packages include daily housekeeping, airport-speed Wi-Fi, and a dedicated GAF patient liaison available by WhatsApp and phone 24 hours a day, 7 days a week. For patients admitted for longer stays (PCCL or open cystolithotomy recovery), GAF arranges optional meal delivery from hospital-approved nutritionists, local SIM cards with data plans, and, where requested, physiotherapy home visit coordination.
TELEMEDICINE CONTINUITY: All patients receive access to the GAF Healthcare patient portal, which stores their operative reports, histopathology/stone crystallography results, discharge summaries, and imaging in a GDPR-compliant, encrypted digital health record accessible by both the patient and their home-country physician. Scheduled teleconsultation slots with the treating urologist are booked at 4 weeks and 12 weeks post-return, ensuring clinical continuity across borders.